Effects of screening on radical prostatectomy efficacy: The prostate cancer intervention versus observation trial

Journal of the National Cancer Institute

Volumn 105, Issue 8, 2013, Pages 546-550

  Xia, Jing ^a   Gulati, Roman ^a   Au, Margaret ^b   Gore, John L ^c   Lin, Daniel W ^c   Etzioni, Ruth ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; HUMAN; INTERVENTION STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; UNITED STATES; WATCHFUL WAITING;

AGED; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RESEARCH DESIGN; SCANDINAVIA; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; WATCHFUL WAITING;

EID: 84876566958     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt017     Document Type: Article

References (7)

1. Wilt T, Brawer MK, Jones K, et al. Radical prostatectomy versus observation for localized prostate cancer. New Engl J Med. 2012;367(3):203-213.
2. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364(18):1708-1717.
3. Wilt TJ, Brawer MK, Barry MJ, et al. The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials. 2009;30(1):81-87.
4. Gulati R, Wever EM, Tsodikov A, et al. What if I don't treat my PSAdetected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev. 2011;20(5):740-750.
5. Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res. 2007;13(2 Pt 1):559-565. (Pubitemid 46225362)
6. Gulati R, Inoue L, Katcher J, et al. Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics. 2010;11(4):707-719.
7. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374-383.